OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) - Spiera, R.; Kuwana, M.; Khanna, D.; Hummers, L.; Frech, T.; Stevens, W.; Gordon, J.; Kafaja, S.; Matucci-Cerinic, M.; Distler, O.; Lee, E.B.; Levy, Y.; et al. (Annals of the Rheumatic Diseases, 2021)
Keywords: Adverse events; Agonists; Animal models; Clinical trials; Demography; Fibrosis; General Biochemistry, Genetics and Molecular Biology; Grants; Immunological tolerance; Immunology; Immunology and Allergy; Mycophenolic acid; Pharmaceuticals; Placebos; Research funding; Rheumatology; Safety; Scleroderma; Systemic sclerosis